Which statement is NOT true regarding insulinoma?
All of the following are known complications of pancreatitis except?
What is the investigation of choice to detect gastrinoma less than 5 mm in size?
Which of the following best assesses the severity of pancreatitis?
Which of the following neuroendocrine tumors of the pancreas is most commonly associated with the given manifestation?

The Duval procedure in chronic pancreatitis involves which of the following?
What is true regarding pancreatic trauma?
What are the treatment options for a pseudocyst of the pancreas?
What is the most common mutation in pancreatic adenocarcinoma?
A 35-year-old man presents with acute pancreatitis. What is the ideal fluid of choice for management?
Explanation: **Explanation:** Insulinoma is the most common functional neuroendocrine tumor (NET) of the pancreas. The hallmark of this condition is the autonomous secretion of insulin, leading to recurrent episodes of hypoglycemia. **Why Weight Loss is NOT true:** In patients with insulinoma, **weight gain** is a classic clinical feature, not weight loss. This occurs for two reasons: 1. **Anabolic Effect:** Insulin is a potent anabolic hormone that promotes lipogenesis and glucose storage. 2. **Hyperphagia:** Patients frequently overeat or consume high-calorie sugary snacks to prevent or relieve the distressing symptoms of hypoglycemia. **Analysis of Incorrect Options:** * **A. Hypoglycemic attacks:** This is the primary clinical manifestation. It typically presents as **Whipple’s Triad**: (1) Symptoms of hypoglycemia during fasting/exercise, (2) Documented low blood glucose (<50 mg/dL), and (3) Relief of symptoms upon glucose administration. * **C. Usually solitary tumor:** Over 90% of insulinomas occur as a single, isolated lesion. Multiple tumors are rare and usually associated with **MEN-1 syndrome**. * **D. Mostly benign tumor:** Approximately 90% of insulinomas are benign and small (<2 cm). Only about 10% are malignant (indicated by local invasion or metastasis). **NEET-PG High-Yield Pearls:** * **Localization:** Most are distributed equally across the head, body, and tail of the pancreas. * **Diagnosis:** The "Gold Standard" is the **72-hour supervised fast** (showing elevated insulin and C-peptide levels during hypoglycemia). * **Imaging:** Intraoperative ultrasound (IOUS) combined with surgical palpation is the most sensitive method for localization. * **Treatment:** Surgical enucleation is the treatment of choice for benign, solitary tumors. Medical management includes **Diazoxide** (inhibits insulin release).
Explanation: **Explanation:** The correct answer is **C. Pancreatic malignancy**. While chronic pancreatitis is a significant risk factor for the eventual development of pancreatic adenocarcinoma, malignancy is considered a **sequela or long-term complication of chronic inflammation**, rather than a direct clinical complication of an episode of pancreatitis itself. **Analysis of Options:** * **Pancreatic Abscess (A):** This is a late complication of acute necrotizing pancreatitis, occurring typically 4+ weeks after the onset. It consists of a circumscribed collection of pus near the pancreas. * **Colonic Necrosis (B):** This is a rare but life-threatening complication. The spread of pancreatic enzymes (proteases and lipases) through the transverse mesocolon can cause fat necrosis, thrombosis of the mesenteric vessels, or direct enzymatic digestion of the colonic wall, leading to necrosis or perforation. * **Pancreatic Fistula (D):** This occurs due to disruption of the pancreatic duct (internal fistula leading to ascites/pleural effusion) or as a result of surgical/percutaneous drainage of a collection (external fistula). **NEET-PG High-Yield Pearls:** * **Most common cause of death in early pancreatitis:** Systemic Inflammatory Response Syndrome (SIRS) and Multi-Organ Dysfunction Syndrome (MODS). * **Most common cause of death in late pancreatitis (after 2 weeks):** Sepsis due to infected pancreatic necrosis. * **Sentinel Loop Sign:** Localized ileus of a jejunal loop seen on X-ray, indicating underlying pancreatitis. * **Cullen’s and Grey Turner’s signs:** Indicate retroperitoneal hemorrhage and are associated with severe necrotizing pancreatitis.
Explanation: **Explanation:** The localization of gastrinomas (Zollinger-Ellison Syndrome) is challenging because they are often small (<2 cm) and frequently located within the "Gastrinoma Triangle." **Why Endoscopic Ultrasound (EUS) is the Correct Answer:** For tumors **less than 5 mm**, EUS is the most sensitive imaging modality (sensitivity >90%). Because the transducer is placed in close proximity to the pancreas and duodenum, it provides high-resolution images that can detect lesions as small as 2–3 mm. It is particularly superior for localizing tumors in the **head of the pancreas**. **Analysis of Incorrect Options:** * **B. Octreotide Scan (Somatostatin Receptor Scintigraphy):** While this is the investigation of choice for **initial global localization** and detecting metastases, its resolution is limited. It often fails to detect lesions smaller than 0.5–1 cm. * **C. CT Scan:** Triple-phase CT is commonly used but has low sensitivity (approx. 30-50%) for small gastrinomas, especially those under 1 cm. * **D. Portal Venous Sampling:** This is an invasive functional study used only when non-invasive imaging fails to localize the tumor. It helps in regionalization rather than precise anatomical localization. **High-Yield Clinical Pearls for NEET-PG:** * **Gastrinoma Triangle (Passaro’s Triangle):** Junction of cystic/common bile duct, junction of 2nd and 3rd parts of the duodenum, and neck/body of the pancreas. 90% of gastrinomas are found here. * **Most common site:** Duodenum (more common than the pancreas). * **Best Initial Test:** Serum Gastrin levels (>1000 pg/mL is diagnostic). * **Screening:** Always screen for **MEN-1 syndrome** in patients with gastrinoma. * **Selective Arterial Secretagogue Injection (SASI) test:** Currently the most sensitive functional test for localization if EUS/SRS are negative.
Explanation: ### Explanation **Correct Answer: C. Ranson Score** The severity of acute pancreatitis is determined by the degree of systemic inflammatory response and organ dysfunction, rather than the magnitude of enzyme elevation. The **Ranson Criteria** is a classic clinical scoring system used to predict the severity and mortality of acute pancreatitis. It assesses 5 parameters at admission and 6 parameters at 48 hours. A score of ≥3 indicates severe pancreatitis, while a score of ≥7 indicates a mortality rate of nearly 50%. **Why other options are incorrect:** * **A. Serial serum amylase levels:** Amylase is a diagnostic marker, not a prognostic one. The absolute level of serum amylase does not correlate with the clinical severity or the extent of pancreatic necrosis. * **B. Stool trypsin levels:** This is primarily used to assess pancreatic exocrine insufficiency (e.g., in chronic pancreatitis or cystic fibrosis), not the acute severity of an inflammatory episode. * **C. Development of ARDS:** While ARDS is a sign of severe systemic involvement (organ failure), it is a *complication* of the disease rather than a comprehensive assessment tool. Scoring systems like Ranson or APACHE II are preferred for overall risk stratification. **High-Yield Clinical Pearls for NEET-PG:** * **Ranson Criteria at Admission (GALAW):** **G**lucose >200, **A**ge >55, **L**DH >350, **A**ST >250, **W**BC >16,000. * **Most sensitive imaging for severity:** Contrast-Enhanced CT (CECT) performed after 72 hours (Balthazar Scoring). * **Most accurate scoring system:** APACHE II (can be used at any time, unlike Ranson). * **Single best laboratory marker for severity:** C-Reactive Protein (CRP) >150 mg/L at 48 hours.
Explanation: ***Glucagonoma*** - **Necrolytic migratory erythema (NME)** is the classic cutaneous manifestation, presenting as erythematous, scaling, and crusting lesions typically around the perineum, groin, and inframammary areas. - Associated with the **4 Ds syndrome**: **Dermatitis** (NME), **Diabetes** mellitus, **Deep vein thrombosis**, and **Depression/weight loss**. *Insulinoma* - Causes **Whipple's triad**: hypoglycemic symptoms, documented low blood glucose, and symptom relief with glucose administration. - Presents with **neuroglycopenic symptoms** like confusion, seizures, and loss of consciousness, not skin manifestations. *Gastrinoma* - Associated with **Zollinger-Ellison syndrome**, causing recurrent **peptic ulcers** and **diarrhea** due to excessive gastrin secretion. - Commonly presents with **abdominal pain** and **gastroesophageal reflux disease (GERD)**, not dermatologic findings. *Somatostatinoma* - Rare tumor causing **somatostatinoma syndrome** with diabetes, **steatorrhea**, and **cholelithiasis** due to somatostatin excess. - Typically presents with **gallbladder disease** and **malabsorption**, without characteristic skin lesions.
Explanation: The **Duval procedure** is a historical drainage operation for chronic pancreatitis. It involves a **distal pancreatectomy (resection of the tail)** followed by an **end-to-end pancreaticojejunostomy**, where the cut surface of the remaining pancreas is anastomosed to a Roux-en-Y limb of the jejunum (caudal decompression). ### Why Option A is Correct: The procedure was designed based on the "chain of lakes" concept of ductal obstruction. By removing the tail and draining the duct from its distal end, it aimed to relieve pressure. However, it is rarely performed today because it fails to provide adequate decompression if there are proximal strictures in the pancreatic head. ### Why Other Options are Incorrect: * **Option B:** Describes the **Puestow procedure**. Unlike the Duval, the Puestow involves a longitudinal opening of the pancreatic duct but still includes a distal splenopancreatectomy. * **Option C:** Refers to the **Beger procedure**, which is a duodenum-preserving pancreatic head resection (DPPHR) used when the disease is localized to the head. * **Option D:** Refers to the **Frey procedure**, which combines local resection of the pancreatic head with a longitudinal (side-to-side) pancreaticojejunostomy (Partington-Rochelle). ### High-Yield Clinical Pearls for NEET-PG: * **Partington-Rochelle Procedure:** The most commonly performed drainage surgery today; it is a **longitudinal pancreaticojejunostomy** without any resection. * **Indication for Surgery:** Chronic pancreatitis with a dilated duct (>6 mm) and intractable pain. * **Whipple Procedure:** Reserved for chronic pancreatitis when malignancy cannot be ruled out in the pancreatic head. * **Summary of Evolution:** Duval (End-to-end) → Puestow (Lateral + Tail resection) → Partington-Rochelle (Lateral only).
Explanation: **Explanation:** Pancreatic trauma is relatively rare due to the organ's retroperitoneal location, but it carries high morbidity. **Why Option D is Correct:** Serum amylase is a sensitive but non-specific marker in pancreatic trauma. While it may be normal initially (in about 20-40% of cases), serial monitoring shows that **amylase levels eventually become elevated in approximately 90% of patients**. It is important to note that the degree of elevation does not necessarily correlate with the severity of the ductal injury. **Why Other Options are Incorrect:** * **Option A:** Solitary involvement is **rare**. Because of the pancreas's central location, 90% of cases involve associated injuries to adjacent organs like the liver, spleen, duodenum, or major vessels. * **Option B:** While blunt trauma (e.g., "handlebar injury" in children or steering wheel impact) is a classic cause, globally, **penetrating trauma** (gunshot or stab wounds) is the more frequent cause of pancreatic injury in many trauma centers. * **Option C:** Surgery is **not always needed**. Grade I and II injuries (minor contusions or lacerations without ductal involvement) are often managed conservatively. Surgery is reserved for Grade III+ injuries involving ductal disruption. **NEET-PG High-Yield Pearls:** * **Investigation of Choice:** Contrast-Enhanced CT (CECT) is the gold standard for stable patients. * **Management Gold Standard:** The integrity of the **Main Pancreatic Duct** is the most important factor determining management. * **Surgical Approach:** Distal to the SMV (body/tail) with duct injury → Distal Pancreatectomy. Proximal to the SMV (head) with duct injury → Wide drainage or Whipple’s (if severe). * **Common Complication:** Pancreatic fistula is the most common complication following trauma.
Explanation: **Explanation:** A pancreatic pseudocyst is a collection of fluid rich in pancreatic enzymes, enclosed by a wall of fibrous or granulation tissue (lacking an epithelial lining). Treatment is indicated for cysts that are symptomatic, enlarging, or complicated (e.g., infection, hemorrhage, or gastric outlet obstruction). **Why "All of the above" is correct:** The management of a pseudocyst depends on its location, the thickness of its wall (maturation), and its relationship to adjacent organs. * **Cystogastrostomy:** The preferred procedure for cysts firmly adherent to the posterior wall of the stomach. It allows internal drainage into the gastric lumen. * **Cystojejunostomy:** Indicated for large cysts or those located in the head/body of the pancreas that cannot be easily drained into the stomach. A Roux-en-Y loop of the jejunum is used for drainage. * **Excision of the cyst:** While less common due to the risk of injury to surrounding structures, excision (or distal pancreatectomy including the cyst) is a definitive option for cysts located in the **tail of the pancreas**. **Clinical Pearls for NEET-PG:** * **Wait and Watch:** Most pseudocysts (<6 cm) resolve spontaneously. Observation is recommended for at least **6 weeks** to allow the cyst wall to "mature" (thicken) before surgical intervention. * **Gold Standard Investigation:** Contrast-Enhanced CT (CECT) is the investigation of choice. * **Internal Drainage:** This is the mainstay of surgical treatment. Percutaneous external drainage is generally avoided due to the high risk of forming a pancreaticocutaneous fistula. * **EUS-guided drainage:** Currently the preferred minimally invasive approach for internal drainage in many centers.
Explanation: **Explanation:** Pancreatic ductal adenocarcinoma (PDAC) follows a well-defined genetic progression model involving the activation of oncogenes and the inactivation of tumor suppressor genes. **1. Why K-ras is correct:** The **K-ras** oncogene (located on chromosome 12p) is the most frequently mutated gene in pancreatic cancer, present in **>90-95% of cases**. It is considered an "initiating" mutation because it occurs very early in the progression from Pancreatic Intraepithelial Neoplasia (PanIN-1) to invasive carcinoma. K-ras mutations lead to constitutive activation of signaling pathways that promote uncontrolled cell proliferation and survival. **2. Why the other options are incorrect:** * **p16 (CDKN2A):** This is the most common **tumor suppressor gene** inactivated in pancreatic cancer (found in ~95% of cases). However, K-ras remains the most common overall mutation and the hallmark initiating event. * **p53 (TP53):** This tumor suppressor gene is mutated in about 50-75% of cases. It typically occurs later in the progression (PanIN-3 stage) compared to K-ras. * **BRAF:** While common in melanoma and colorectal cancers, BRAF mutations are rare in pancreatic adenocarcinoma, though they may be seen in a small subset of K-ras wild-type tumors. **High-Yield Clinical Pearls for NEET-PG:** * **Sequence of mutations:** K-ras (Early/PanIN-1) → p16 (Intermediate/PanIN-2) → p53 & SMAD4/DPC4 (Late/PanIN-3). * **SMAD4 (DPC4):** Inactivation is relatively specific to pancreatic cancer and is often associated with poor prognosis and distant metastasis. * **Tumor Marker:** CA 19-9 is the most common marker used for monitoring, but it is not used for screening. * **Risk Factors:** Smoking is the most consistent environmental risk factor.
Explanation: **Explanation:** **1. Why Isotonic Crystalloid is Correct:** The cornerstone of early management in acute pancreatitis is **aggressive fluid resuscitation**. Acute pancreatitis leads to significant fluid loss due to "third-spacing" (sequestration of fluid into the retroperitoneum and peritoneal cavity), vomiting, and diaphoresis. **Isotonic crystalloids** (specifically **Ringer’s Lactate** or Normal Saline) are the fluids of choice because they are iso-osmotic to plasma, effectively expanding the intravascular volume without causing major electrolyte shifts. Ringer’s Lactate is often preferred over Normal Saline as it may reduce the risk of hyperchloremic metabolic acidosis and has been shown to decrease systemic inflammation (SIRS). **2. Why Other Options are Incorrect:** * **B. Hypertonic crystalloid:** These fluids (e.g., 3% NaCl) draw water out of the cells into the vascular space. In pancreatitis, they can lead to severe cellular dehydration and hypernatremia, worsening the metabolic profile. * **C. Hypotonic crystalloid:** These fluids (e.g., 0.45% NaCl) shift fluid from the intravascular space into the cells/interstitium. This would worsen the third-spacing and exacerbate hypotension and organ hypoperfusion. * **D. Vasopressin:** This is a vasoconstrictor. Using vasopressors before adequate fluid resuscitation is contraindicated as it further compromises pancreatic microcirculation, potentially turning interstitial pancreatitis into necrotizing pancreatitis. **3. High-Yield Clinical Pearls for NEET-PG:** * **Fluid of Choice:** Ringer’s Lactate (RL) is superior to Normal Saline (NS) in reducing SIRS. * **Rate:** Initial resuscitation is usually 250–500 mL/hr unless cardiovascular comorbidities exist. * **Monitoring:** The goal is to maintain a urine output of **>0.5 mL/kg/hr** and a reduction in Hematocrit/BUN levels. * **Timing:** The "Golden Period" for fluid resuscitation is the first **12–24 hours**; delayed resuscitation increases the risk of pancreatic necrosis.
Pancreatic Anatomy and Physiology
Practice Questions
Acute Pancreatitis
Practice Questions
Chronic Pancreatitis
Practice Questions
Pancreatic Pseudocysts
Practice Questions
Pancreatic Adenocarcinoma
Practice Questions
Cystic Neoplasms of Pancreas
Practice Questions
Neuroendocrine Tumors of Pancreas
Practice Questions
Pancreatic Trauma
Practice Questions
Pancreatectomy Techniques
Practice Questions
Whipple Procedure
Practice Questions
Pancreatic Anastomosis
Practice Questions
Complications of Pancreatic Surgery
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free